title: [A prospective randomized control clinical trial about clopidogrel combined with warfarin versus clopidogrel alone in the prevention of restenosis after femoral-popliteal artery angioplasty].
abstract: OBJECTIVE
  Using two antithrombotic treatment (clopidogrel vs. clopidogrel combined warfarin) strategies after femoral-popliteal artery angioplasty prospectively, to evaluate which strategy is more effective for the restenosis prevention.
  
  
  METHODS
  Totally 50 patients referred for endovascular treatment (including the percutaneous transluminal angioplasty (PTA) and stent implantation) of the superficial femoral artery and popliteal artery from January 2008 to May 2009 were randomly divided into clopidogrel group (group A, 25 cases, 30 limbs) and clopidogrel plus warfarin group (group B, 25 cases, 33 limbs) before operation. Clinical outcomes and restenosis rate of the target lesions were evaluated at 3, 6 and 12 months after operation.
  
  
  RESULTS
  Totally 88 patients were screened for participation in the study, 56 patients were included after the follow-up of 12 months. At 3 months, the rates of restenosis were 16.7% in group A and 18.2% in group B (χ² = 0.025, P = 0.874). At 6 months, the accumulated restenosis rates were 36.7% in group A and 36.4% in group B (χ² = 0.001, P = 0.98). At 12 months, the accumulated restenosis rates were 53.3% in group A and 42.4% in group B (χ² = 0.75, P = 0.387). Analysis for the critical limb ischemia sub-group showed that follow-up of 12 months, the accumulated restenosis rate was 8/10 in group A and 6/12 in group B (χ² = 1.023, P = 0.312).
  
  
  CONCLUSIONS
  The clopidogrel alone treatment for PTA or PTA plus stent implantation of femoral popliteal artery has no statistically significant difference in comparison with the clopidogrel combined warfarin treatment in terms of the cumulative vascular restenosis rate at 3, 6, 12 months postoperatively.
authors.affiliation: Department of Vascular Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital, China.
authors.forename: Gang-zhu
authors.initials: GZ
authors.lastname: Liang
authors.forename: Fu-xian
authors.initials: FX
authors.lastname: Zhang
authors.forename: Xiao-yun
authors.initials: XY
authors.lastname: Luo
authors.forename: Chang-ming
authors.initials: CM
authors.lastname: Zhang
authors.forename: Lu
authors.initials: L
authors.lastname: Hu
authors.forename: Ya-ping
authors.initials: YP
authors.lastname: Feng
authors.forename: Lu-yuan
authors.initials: LY
authors.lastname: Niu
authors.forename: Huan
authors.initials: H
authors.lastname: Zhang
authors.forename: Bing-bing
authors.initials: BB
authors.lastname: Ma
authors.forename: Hao-shan
authors.initials: HS
authors.lastname: Qi
authors.forename: Mei-mei
authors.initials: MM
authors.lastname: Guo
authors.forename: Yan-Yu
authors.initials: YY
authors.lastname: Long
authors.forename: Hai-Lei
authors.initials: HL
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000800:Angioplasty, Balloon; D001157:Arterial Occlusive Diseases / Q000209:etiology / Q000517:prevention & control*; D000077144:Clopidogrel; D005260:Female; D005263:Femoral Artery / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D011150:Popliteal Artery / Q000601:surgery; D011183:Postoperative Complications / Q000517:prevention & control; D011446:Prospective Studies; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D014859:Warfarin; D000077144:Clopidogrel; D013988:Ticlopidine